- Darolutamide in the treatment of metastatic castrate-resistant prostate cancer2022 | First Faculty of Medicine
- New hormonal agents in castration-resistant prostate cancer2013 | First Faculty of Medicine
- Treatment options of non-metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine
- Cabazitaxel in the treatment of patients with metastatic castration-resistant prostate cancer2014 | First Faculty of Medicine
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Circulating tumor cells in castration-resistant prostate cancer as a part of systemic treatment individualization.Publication without faculty affiliation
- Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer2014 | Third Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Publication without faculty affiliation
- Prognostic significance of circulating tumor cells in castration resistant prostate cancerPublication without faculty affiliation
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerPublication without faculty affiliation
- Are circulating tumor cells a future weapon in the fight against castration resistant prostate cancer?Publication without faculty affiliation
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- Detection and characterization of circulating tumor cells in patients with castration resistant prostate cancerPublication without faculty affiliation
- Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy2018 | First Faculty of Medicine
- Circulating tumor cells as a biomarker for the patients with castration resistant prostate cancerPublication without faculty affiliation
- Detection and characterisation of circulating tumor cells in patients with castration resistant prostate cancer2012 | First Faculty of Medicine
- ARTA treatment of metastatic castration-resistant prostate cancer - case report2021 | First Faculty of Medicine
- New possibilities in monitoring patients suffering from castration resistant prostate cancer by using circulating tumor cells2013 | First Faculty of Medicine, Faculty of Physical Education and Sport
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant prostate cancer2014 | First Faculty of Medicine
- Abiraterone acetate and quality of life of castration-resistant prostate cancer patients2013 | First Faculty of Medicine
- Radiation-223 Treatment of a 72-year-old Patient with Castration-Resistant Prostate Cancer and Painful Bone Metastases2019 | Faculty of Medicine in Hradec Králové
- Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest(R) System for Detection of Circulating Tumor Cells2016 | First Faculty of Medicine
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy2023 | First Faculty of Medicine
- Enzulutamide in treatment in patients with metastatic castration-resistant prostate cancer after previous chemotherapy2017 | First Faculty of Medicine
- Treatment of prostate cancer in the Czech Republic in 2016: outcomes of workshops on metastatic castration-resistant prostate cancer (mCRPC)2017 | Second Faculty of Medicine
- Prostate-specific antigen level and detection of circulating tumour cells in castration-resistant prostate cancerPublication without faculty affiliation
- Treatment of non‐metastatic castration‐resistant prostate cancer2023 | Third Faculty of Medicine
- Analysis of european patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy2014 | First Faculty of Medicine
- Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy2016 | First Faculty of Medicine
- An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)2019 | Faculty of Medicine in Pilsen